Disease activity in different treatment groups.

<p>Treatment groups as baseline of patients with EDA or NEDA one year later.</p

Change in disability after one year.

<p>The patient group as a whole had stable disability scores from baseline to follow-up. NEDA patients improved in disability, while the EDA patients showed a disability progression at one-year follow-up.</p

Patients in different treatment groups at baseline and follow-up.

<p>The arrows indicate change in treatment groups of patients from baseline to follow-up. Eight patients changed first line treatment during the period, not illustrated.</p

Evidence of disease activity at one-year follow-up.

<p>54% of the patients were classified as NEDA after one year, while 46% of the patients showed either one or more evidences of disease activity.</p

Annual gray matter atrophy rates.

<p>ANOVAs with Bonferroni-corrected post-hoc tests revealed that subcortical annual atrophy rates differed between patients with evidence of disease activity and healthy controls. Patients with no evidence of disease activity had similar atrophy rates as controls. Cortical atrophy rates were similar in all groups.</p

Baseline MRI characteristics of patients and controls.

<p>WM: white matter, GM: gray matter. The total neuroanatomical volumes, i.e. of both hemispheres combined, are presented. ANCOVAs were performed to test for differences in neuroanatomical volumes between the groups.</p><p>Baseline MRI characteristics of patients and controls.</p

Annual percent change of MRI volumes of patients and controls.

<p>Annual percent change for patients and controls. Independent samples t-tests and ANOVAs with Bonferroni-corrected post-hoc tests were used to test for differences between the groups. Significant differences in atrophy rates were identified between:</p><p>¹ RRMS and HC (p-value<0.001) and,</p><p>² EDA and HC(p-value<0.001).</p><p>Annual percent change of MRI volumes of patients and controls.</p